Articles published by Biomunex Pharmaceuticals

Biomunex Announces Strategic Artificial Intelligence Collaborations to Further Accelerate the Discovery and Development Processes of Its Innovative Pipeline of Cancer Immunotherapies

Today 8:00 EDT

From Biomunex Pharmaceuticals

Via Business Wire

Biomunex Pharmaceuticals will showcase its MAIT Engager Platform during the 11th Annual Oncology Innovation Forum in San Francisco

January 08, 2026

From Biomunex Pharmaceuticals

Via Business Wire

Biomunex to Present Preclinical Data of its MAIT Engager Platform in Immuno-Oncology at 2025 SITC Annual Meeting

November 07, 2025

From Biomunex Pharmaceuticals

Via Business Wire

Biomunex Signs Exclusive Licensing Agreement With Institut Curie to Develop MAIT Engagers, a New Class of Bispecific Antibodies in Immuno-oncology

March 04, 2024

From Biomunex Pharmaceuticals

Via Business Wire

Biomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer

January 24, 2024

From Biomunex Pharmaceuticals

Via Business Wire

Biomunex Pharmaceuticals, a French Company Specialized in Immunotherapy, Presents the Latest Preclinical Results on Its Disruptive MAIT Cell Redirection Approach For Cancer Treatment at the 2023 AACR Annual Meeting

April 12, 2023

From Biomunex Pharmaceuticals

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Biomunex Pharmaceuticals

Starting at $3.75/week.

Subscribe Today